FRAXA Drug Validation Initiative (FRAXA-DVI)

The FRAXA Drug Validation Initiative (FRAXA-DVI) provides speedy, cost-effective, objective preclinical testing to validate investigational and repurposed compounds for Fragile X.

Read More »
Justin Cowan, PhD

Treatment of Fragile X Syndrome via Dopamine Enhancers and Glutamate Inhibitors

In Fragile X mice, low dopamine signaling and excessive glutamate activity were targeted with dual therapy: dopamine enhancers plus glutamate inhibitors.

Read More »
Juan Bacigalupo

In Vitro Coherent Network Activity

This work revealed that Fragile X neurons form disordered network dynamics—laying groundwork for using network activity as a treatment-screening metric.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (38)